84 results about "Personalized therapy" patented technology

An method and system that allows a patient to access stored preset patient therapy programs, that are resident in a medical device such an implantable pump or a combination medical device having an implantable pump and a implantable neural stimulator, and to create personalized therapy programs or automatic timing therapy programs from preset therapy programs to accommodate the patient's particular activity. Alternatively, the patient can select and access stored preset patient therapy programs and combine at least two modified or unmodified preset therapy programs to create personalized therapy programs.

The present disclosure provides methods of diagnosing a subject as having a pulmonary disease or disorder, e.g., an eosinophilic disease or disorder based on the determination of white blood cell ratios. The disclosure also provides white blood cell ratio-based methods of treating, prognosing, or monitoring a pulmonary disease or disorder, as well as methods of methods of predicting a dosage regimen, identifying a candidate therapeutic agent, identifying a patient as a candidate for a therapeutic agent, and methods of designing a personalized therapy.

Methods, devices and systems for acquiring information useful to support a patient in implementing and adhering to a medically prescribed therapy plan are provided. The therapy may incorporate biofeedback methods and / or personalized therapy aspects. A method includes steps of receiving, by a receiving device, biometric information associated with an ingestible event marker; analyzing, by a computing device having a microprocessor configured to perform a biometric information analysis, the biometric information; and determining a therapeutic recommendation at least partly on the basis of the analysis and / or integrating biofeedback techniques into patient therapy or activity. A system includes a biometric information module to receive biometric information associated with an ingestible event marker; an analysis module to analyze the biometric information; and a determination module to optionally determine and communicate a therapeutic recommendation at least partly on the basis of the analysis.

The disclosed technology describes compositions and methods useful for providing cell based therapy. For example, one embodiment of cell based therapy involves the regeneration of injured tissue and / or promoting wound healing. Certain embodiments provide improved therapeutic compositions using microbubbles by delivering biological progenitor cells to the injured tissues. The administration of the microbubbles is directed by acoustic radiation forces that interact with embodiments of microbubbles comprising an acoustically active gas. As such, a high efficiency of progenitor cell delivery to injured tissue is realized. One advantage of this technique over targeted delivery of pharmaceutical compounds, is that the delivered progenitors cells may be derived from the patient (i.e., personalized therapy), thereby avoiding side effects, allergic reactions, and overall problems associated with refractive drug responses.

The present invention provides methods for personalized therapeutic management of a disease in order to optimize therapy and / or monitor therapeutic efficacy. In particular, the present invention comprises measuring an array of one or a plurality of biomarkers at a plurality of time points over the course of therapy with a therapeutic agent to determine a mucosal healing index for selecting therapy, optimizing therapy, reducing toxicity, and / or monitoring the efficacy of therapeutic treatment. In certain instances, the therapeutic agent is a TNFα inhibitor for the treatment of a TNFα-mediated disease or disorder.

Methods, devices and systems for acquiring information useful to support a patient in implementing and adhering to a medically prescribed therapy plan are provided. The therapy may incorporate biofeedback methods and / or personalized therapy aspects. A method includes steps of receiving, by a receiving device, biometric information associated with an ingestible event marker; analyzing, by a computing device having a microprocessor configured to perform a biometric information analysis, the biometric information; and determining a therapeutic recommendation at least partly on the basis of the analysis and / or integrating biofeedback techniques into patient therapy or activity. A system includes a biometric information module to receive biometric information associated with an ingestible event marker; an analysis module to analyze the biometric information; and a determination module to optionally determine and communicate a therapeutic recommendation at least partly on the basis of the analysis.

The invention discloses a tinnitus diagnostic test device. The tinnitus diagnostic test device is characterized by comprising an all-digital audio tone signal synthetic generator and an operating module. The all-digital audio tone signal synthetic generator generates various audio tone signals of tone, melody, rhythm and volume. The operating module operates the all-digital audio tone signal synthetic generator to comprehensively evaluate tinnitus and output tinnitus diagnosis audio tone signals. The all-digital audio tone signal synthetic generator comprises a composite acoustic signal generation module, a tonal signal generation module, a noise signal generation module and a recording signal generation module, wherein the modules generate specific audio tone signals respectively. The tinnitus diagnostic test device is capable of precisely restoring or simulating audio tone information of various types of tinnitus, differed due to personal difference, left and right ear difference and time and environmental factors and observed clinically, so that fine basis for providing patients with personalized therapies is provided and tinnitus treatment is more effective.

The subject invention pertains to a non-human animal model of human cancer, methods of producing a non-human animal model of human cancer, methods of using a non-human animal model to propagate human cancer cells, methods of using a non-human animal model to study cancer, methods of using a non-human animal model to screen potential treatments for a subject's cancer, methods of using a non-human animal model for treating cancer in a subject (providing personalized therapy), methods of using a non-human animal model for identifying a biomarker of cancer treatment; and methods of using a non-human animal model for selecting cancer patients for a clinical trial.

The present invention provides methods for personalized therapeutic management of a disease in order to optimize therapy and / or monitor therapeutic efficacy. In particular, the present invention comprises measuring an array of one or a plurality of biomarkers at a plurality of time points over the course of therapy with a therapeutic agent to determine a mucosal healing index for selecting therapy, optimizing therapy, reducing toxicity, and / or monitoring the efficacy of therapeutic treatment. In certain instances, the therapeutic agent is a TNFα inhibitor for the treatment of a TNFα-mediated disease or disorder.

A method for generating an immune score, the method comprising the steps of: (i) determining a qualitative and / or quantitative assessment of tumor infiltrating lymphocytes in a sample; (ii) determining a qualitative and / or quantitative assessment of T-cell receptor signaling in the sample; (iii) determining a qualitative and / or quantitative assessment of mutation burden in the sample; (iv) generating, using a predictive algorithm, an immune score based on the determined qualitative and / or quantitative assessment of tumor infiltrating lymphocytes, the determined qualitative and / or quantitative assessment of T-cell receptor signaling, and the determined qualitative and / or quantitative assessment of mutation burden.

The invention discloses a genetic evaluation and suit method for individualized tumor therapy. The genetic evaluation and package method includes steps of: 1) extracting a DNA sample of a subject; 2) carrying out target gene PCR amplification, purification, fragmentation and fluorescein labeling on the sample DNA; 3) carrying out gene chip hybridization on fluorescein labeled PCR products to detect SNP sites of the target gene; and 4) analyzing curative effect and toxicity of antitumor drug on the subject, according to the genetic typing results obtained in the step 3). Therapeutic effect evaluation of tumor patient can be conducted through the related genetic typing, thus formulating the most scientific individualized therapy plan to improve efficacy, reduce or even avoid the toxic and side effects.

The invention discloses a method for utilizing a malignant pleural effusion for separately culturing primary cancer cells. The method comprises the steps of putting a pleural effusion sample into a sample collecting liquid, and centrifuging to remove a supernatant; adding a red blood cell lysis buffer for removing a red blood cell, adding a PBS buffer solution for washing the cells, and centrifuging to remove a supernatant; using a KL culture medium for resuspending a cell precipitate, inoculating in a culture flask, and culturing in a culture box. When the cells are proliferated to more than85 percent of abundance, the cells are washed through the PBS buffer solution, pancreatin-EDTA is digested, and a stop buffer neutralizes digestion reaction; the cells are centrifugally collected, areresuspended through the KL culture medium, and inoculated in the cell flask according to the proportion so as to be subcultured. The primary cancer cells of the pleural effusion obtained by separatedculture through the method provided by the invention can be applied to related research of physiology, pharmacy, new drug research and development and the like, exploration of pathogenesis of relateddiseases of a lung cancer, detection of drug sensitivity of different drugs, screening of anti-cancer drugs, new drug research and development, and establishment of a personalized treatment program aiming at a patient.

The invention discloses a preparation method of pluripotent stem cells of a xeroderma pigmentosum patient. The method comprises the steps that by means of an iPSC technology, skin fibroblast cells of the xeroderma pigmentosum patient are reprogrammed into specific induced pluripotent stem cells through a non-integration episomal plasmid electrophoretic transfer method and directionally divided into nerve cells which show extreme sensitivities to UV in vitro, cell apoptosis is prone to occurrence, and some clues are provided for neurodegenerative diseases of the xeroderma pigmentosum patient. In addition, the mutational neural stem cells and neurones which carry genes of the patient can serve as an effective platform to conduct efficient and high-throughout personalized drug screening, and a foundation is laid for disease study, disease model development, research on pathogenesis of diseases and treatment on the diseases. A huge application prospect is achieved in personalized treatment and translational medicine.

Methods and kits are provided for detecting polymorphisms in carboxylesterase-1 (CES1). Several single nucleotide polymorphisms (SNPs) in CES1 in humans, and methods for detecting the same, are provided (e.g., Gly143Glu, 12754T>del). Results indicate that the Gly143Glu (9486G>A) polymorphism has an allelic frequency of 1.5% in the Caucasian population. Polymorphisms of the present invention may alter the function of the carboxylesterase-1 enzyme (hCES1). Thus, the methods and kits of the present invention may be used to personalize a therapy and / or avoid adverse consequences of altered metabolism of a therapeutic or compound (e.g., enalapril, methylphenidate, etc.) which may result due to a CES1 polymorphism. In addition, recombinant cells lines overexpressing wild-type CES1 or expressing CES1 mutants are provided. Such cell lines may be used to assess the effects of candidate compounds on CES1, and the action of CES1 on these candidate compounds.

Methods and devices for clustering a plurality of sub-networks of a larger interaction network using an enhanced hierarchical clustering algorithm are disclosed. The methods provide expression based sub-network generation using differentially expressed markers. The enhanced hierarchical clustering algorithm clusters the generated sub-networks based on a user defined customizable similarity coefficient. The methods use non-Boolean links to cluster similar sub-networks. This provides consideration of indirect relationships among sub-networks. The customizable similarity coefficient enables the methods to be used for diverse applications such as biomarker detection, patient stratification, personalized therapy, drug efficacy prediction, genetic similarity analysis in genetic diseases. The methods enable patient grouping based on the enhanced hierarchical clustering algorithm.

The invention discloses medical applications of four buxus alkaloids compounds in the preparation of antitumor medicines. Experiment results show that the four compounds KBA01, KBA02, KBA03 and KBR18, under the condition of concentration without toxicity to wild normal mouse embryonic fibroblast cells, can selectively kill mouse tumor cells with tumor specific mutant genes p53 and Ras; accordingly, the compounds are very strong in killing activity to human colon cancer cell strains with p53 mutants, but not strong in killing activity to human wild colon cancer cell strains with p53 mutants; and as shown in a GFP (Green Fluorescence Protein) reporter vector screening system of a gene promoter, the compounds KBA02 and KBA03 can activate a promoter of a cancer suppressor gene p16. The characteristics indicate that the compounds from the four buxus plant origins have application potentials for preparing personalized treatment medicines aiming at the tumor mutant genes p53 and Ras as well as the cancer suppressor gene p16.

The invention provides a diagnosis and treatment-integrated physiotherapy device. The diagnosis and treatment-integrated physiotherapy device comprises an image collecting system used for collecting human tissue images; a physical factor output control system used for generating physical treatment factors with corresponding intensity and working on human tissue; a master control system which receives the human tissue images collected by the image collecting system, analyzes the images, generates diagnosis results and therapy schemes and outputs the therapy schemes to the physical factor outputcontrol system. The device achieves automatic and quantized diagnosis of patients by using image diagnosis techniques such as visual light and infrared light and automatically generates therapy schemes through a large number of prescription templates stored in the master control system, thereby being highly scientific and objective. The device can provide a personalized therapy scheme according to quantized values of a disease of each patient, thereby improving the accuracy and effectiveness of physiotherapy; the device performs diagnosis and assessment on a patient in each physiotherapy andadjusts the therapy scheme according to the assessment result, thereby improving the flexibility and adaptability of therapy schemes.

The invention provides novel personalized therapies, kits, transmittable forms of information and methods for use in treating patients having cancer, wherein the cancer is MTAP-deficient and / or MTA-accumulating and thus amenable to therapeutic treatment with a PRMT5 inhibitor. Kits, methods of screening for candidate PRMT5 inhibitors, and associated methods of treatment are also provided.

The invention discloses a scoring method for quantifying a TIME infiltration mode; the score for quantifying the TIME infiltration mode is called as a TIME index (TI), the TI is an excellent prognosisprediction index in hepatocellular carcinoma and pancreas carcinoma, and the performance of the TI in predicting immunotherapy response is superior to that of other 11 biomarkers. The results can strengthen the understanding of the immune microenvironment and guide more effective personalized treatment, and the TIME1 is characterized by immune cell depletion and cell proliferation and correspondsto immunodeficiency types; tIME2 is characterized by being in an immunosuppression state, and a potential immune escape mechanism of each phenotype is emphasized corresponding to immunosuppression: TIME1 is characterized by tumor infiltration leukocyte deficiency and tumor antigen presentation capability defects; the TIME2 has more immunosuppressive cells; the TIME3 is rich in immunosuppressive cytokines and immune checkpoint molecules.

The present invention relates to a method of identifying, separating and characterizing a cell or a population of cells, by capturing at the cell surface, secreted soluble substances (such as an immunoglobulin) that cell or population of cell secrete. This is achieved by combing on a heterodimerically-tethered multispecific protein complex combining a binding specificity for the secreted molecule and a binding specificity for a surface antigen specific for that cell or population of cells. This method may be used in research and experimental purposes, such as patients' stratification in preparation of clinical trials or personalized therapies by identifying cell populations relevant to a pathology and / or prognosis.

The invention belongs to the technical field of biological medicines, and discloses application of an METTL2 gene in preparation of a kit for detecting the treatment sensitivity of colorectal cancer fluorouracil drugs. The application is based on the invention. The inventor discovers that METTL2 protein expression can enhance the sensitivity of colorectal cancer cells to 5-FU, and tumor tissue high expression METTL2 of a colorectal cancer patient is positively correlated with good prognosis of 5-FU chemotherapy. Therefore, a clinician can determine whether the colorectal cancer patient is suitable for fluorouracil drug treatment or not according to the expression condition of the METTL2 gene of the colorectal cancer patient, and formulate a personalized treatment scheme.

The present invention describes an integrated apparatus that enables identification of migratory cells directly from a specimen. The apparatus only requires a small number of cells to perform an assay and includes novel topographic features which can reliably differentiate between migratory and non-migratory cell populations in a sample. Both the spontaneous and chemotactic migration of cancer cells may be measured to distinguish between subpopulations within a tumor sample. The migratory cells identified using the apparatus and methods of the present invention may be separated and further analyzed to distinguish factors promoting metastasis within the population. Cells in the apparatus can be treated with chemotherapeutic or other agents to determine drug strategies to most strongly inhibit migration. The use of optically transparent materials in some embodiments allows a wide range of imaging techniques to be used for in situ imaging of migratory and non-migratory cells in the apparatus. The apparatus and methods of the present invention are useful for predicting the metastatic propensity of tumor cells and selecting optimal drugs for personalized therapies.

The disclosure provides methods for treating a subject having a type I IFN-mediated disease or disorder comprising administration of a fixed does of an anti-interferon alpha receptor antibody. The disclosure also provides methods for suppressing a type I interferon (IFN) gene signature (GS) in a subject. In addition, the disclosure provides methods of prognosing or monitoring disease progression in a subject having a type I IFN-mediated disease or disorder, methods of predicting a dosage regimen, methods of identifying a candidate therapeutic agent, methods of identifying a patient as a candidate for a therapeutic agent, and methods of designating a personalized therapy.

The invention discloses a cancer gene detection kit based on a second-generation sequencing probe capture method. The cancer gene detection kit comprises quality control materials, library building reagents and an RNA probe; quality control materials: a negative quality control material and a positive quality control material; library building reagents: a tail end repairing and A adding reagent, ajoint adding reagent, an amplification reagent, a hybridization reagent, a capture reagent and an amplification reagent; the RNA probe is a probe panel; the synthesis type of the RNA probe is an RNAsingle strand; the length interval is 90-120 nt; and biotin is marked. The cancer gene detection kit in the invention aims at patients with lung cancer, colorectal cancer, breast cancer and ovarian cancer. Detection of 18 genes panel is carried out; the receptivity of medicines, such as targeting and chemotherapy, on a patient is comprehensively interpreted from the gene level; according to the difference of individual gene levels, an accurate personalized treatment scheme is made; immune medication treatment is guided; the sensitivity and toxic and side effects of chemotherapy drugs are predicted; a medication prognosis condition is dynamically monitored, etc.

Electronic arrangement (100) for use in providing therapeutic intervention to a user suffering from a medical condition, optionally to reduce fear of movement and improve function in patients with chronic pain, via virtual reality (VR) or augmented reality (AR), comprising a reproduction equipment (116) comprising a VR and / or AR projection device configured to represent virtual content, comprising an immersive virtual environment or a virtual part of a virtually augmented environment, to the user; user monitoring equipment (114, 114A, 114B) configured to obtain measurement data regarding the user, including motion, location, position, and / or biometric data; and a control system (118, 118A, 118B, 118C), at least functionally connected to the reproduction equipment and the user monitoring equipment, and configured to dynamically determine a personalized therapeutic program including the virtual content for representation via the reproduction equipment, based on the measurement data, wherein the therapeutic program comprises at least two domains of different virtual content, one or more of the domains involving behavior-change con-tent and at least one other domain involving user-activating virtual content indicative of a series of tasks to be conducted by the user having regard to the virtual content through associated therapeutic behavior, such as physical activity or problem solving, in the physical world outside the virtual environment or virtually augmented environment and tracked by the measurement data. A related method is presented.

Described herein is a non-invasive quantitative positron emission tomography (PET) nanoreporter technology that allows personalized therapeutic outcome prediction. In a breast cancer mouse model, it was demonstrated that co-injecting Doxil and a Zirconium-89 nanoreporter (89Zr-NRep) enabled highly precise doxorubicin (DOX) quantification. Imaging 89Zr-NRep via PET revealed remarkable Doxil accumulation heterogeneity independent of tumor size.

The disclosure is directed to novel personalized therapies and methods for treating ankylosing spondylitis (AS). Specifically, this disclosure relates to methods of treating a patient having AS by selectively administering an IL-17 antagonist, e.g., an IL-17 antibody, such as secukinumab, to the AS patient on the basis of that patient being predisposed to have a favorable response to treatment with the IL-17 antagonist. Also disclosed herein are diagnostic methods and transmittable forms of information useful in predicting the likelihood that a patient having AS will respond to treatment with an IL-17 antagonist, e.g., an IL-17 antibody, such as secukinumab.